Insmed Inc. Files Q1 2025 10-Q Report
Ticker: INSM · Form: 10-Q · Filed: 2025-05-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, SEC filing
TL;DR
**Insmed Q1 2025 10-Q filed. Financials and ops update.**
AI Summary
Insmed Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business developments are presented within this report.
Why It Matters
This 10-Q filing provides investors and analysts with the latest financial health and strategic direction of Insmed Inc., crucial for understanding its market position and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Insmed faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (The end date for the financial reporting period.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially filed with the SEC.)
- 12-31 — Fiscal Year End (Indicates the company's fiscal year concludes on December 31st.)
- 2024-03-31 — Prior Year Q1 End Date (Provides a comparative period for Q1 2024.)
- 2023-12-31 — Prior Year End Date (Provides a comparative period for the end of fiscal year 2023.)
Key Players & Entities
- INSMED Inc (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250508 (date) — Filing Date
- VA (location) — State of Incorporation
- NJ (location) — Business Address State
- 08807 (location) — Business Address Zip Code
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 8, 2025.
What is Insmed Inc.'s state of incorporation?
Insmed Inc.'s state of incorporation is Virginia (VA).
What is the company's fiscal year end date?
Insmed Inc.'s fiscal year ends on December 31st.
What is the business address of Insmed Inc.?
The business address is 700 US Highway 202/206, Bridgewater, NJ 08807.
From the Filing
0001104506-25-000026.txt : 20250508 0001104506-25-000026.hdr.sgml : 20250508 20250508065951 ACCESSION NUMBER: 0001104506-25-000026 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250508 DATE AS OF CHANGE: 20250508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSMED Inc CENTRAL INDEX KEY: 0001104506 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 541972729 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-30739 FILM NUMBER: 25923758 BUSINESS ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 908-977-9900 MAIL ADDRESS: STREET 1: 700 US HIGHWAY 202/206 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: INSMED INC DATE OF NAME CHANGE: 20000128 10-Q 1 insm-20250331.htm 10-Q insm-20250331 0001104506 false --12-31 2025 Q1 http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember http://fasb.org/us-gaap/2024#ProductMember 0.0307692 127 156 215 363 59 29 205 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure insm:reportingUnit insm:sale insm:day insm:quarterly_payment insm:payment insm:performanceCondition insm:days insm:segment 0001104506 2025-01-01 2025-03-31 0001104506 2025-05-02 0001104506 2025-03-31 0001104506 2024-12-31 0001104506 2024-01-01 2024-03-31 0001104506 us-gaap:CommonStockMember 2023-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001104506 us-gaap:RetainedEarningsMember 2023-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001104506 2023-12-31 0001104506 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001104506 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001104506 us-gaap:CommonStockMember 2024-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001104506 us-gaap:RetainedEarningsMember 2024-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001104506 2024-03-31 0001104506 us-gaap:CommonStockMember 2024-12-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001104506 us-gaap:RetainedEarningsMember 2024-12-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001104506 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001104506 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001104506 us-gaap:CommonStockMember 2025-03-31 0001104506 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001104506 us-gaap:RetainedEarningsMember 2025-03-31 0001104506 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001104506 insm:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueProductLineMember 2025-01-01 2025-03-31 0001104506 insm:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueProductLineMember 2024-01-01 2024-03-31 0001104506 insm:CustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueProductLineMember 2025-01-01 2025-03-31 0001104506 insm:CustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueProductLineMember 2024-01-01 2024-03-31 0001104506 insm:CustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueProductLineMember 2025-01-01 2025-03-31 0001104506 insm:CustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueProductLineMember 2024-01-01 2024-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001104506 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001104506 us-gaap:Res